X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (80321) 80321
Newspaper Article (4108) 4108
Newsletter (2744) 2744
Book Chapter (374) 374
Transcript (187) 187
Dissertation (169) 169
Magazine Article (168) 168
Government Document (112) 112
Book / eBook (71) 71
Web Resource (40) 40
Publication (33) 33
Conference Proceeding (30) 30
Trade Publication Article (20) 20
Book Review (14) 14
Streaming Video (10) 10
Reference (8) 8
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
angiogenesis (54919) 54919
humans (50295) 50295
animals (29872) 29872
oncology (21967) 21967
female (21630) 21630
cancer (20813) 20813
male (20289) 20289
mice (16748) 16748
vascular endothelial growth factor (15088) 15088
expression (14735) 14735
angiogenesis inhibitors (12837) 12837
angiogenesis inhibitors - therapeutic use (12071) 12071
endothelial growth-factor (11819) 11819
metastasis (11511) 11511
apoptosis (11013) 11013
middle aged (10817) 10817
research (10579) 10579
tumors (10249) 10249
aged (9657) 9657
proteins (9481) 9481
bevacizumab (9167) 9167
cell biology (8977) 8977
care and treatment (8752) 8752
cell line, tumor (8591) 8591
analysis (7899) 7899
gene expression (7665) 7665
adult (7596) 7596
angiogenesis inhibitors - pharmacology (7153) 7153
biochemistry & molecular biology (7109) 7109
vegf (6873) 6873
kinases (6783) 6783
growth (6774) 6774
ophthalmology (6763) 6763
cells (6726) 6726
signal transduction (6705) 6705
chemotherapy (6372) 6372
health aspects (6071) 6071
neovascularization (5991) 5991
pharmacology & pharmacy (5819) 5819
vascular endothelial growth factor a - antagonists & inhibitors (5806) 5806
cell proliferation (5783) 5783
treatment outcome (5743) 5743
cells, cultured (5710) 5710
angiogenesis inhibitors - administration & dosage (5522) 5522
rats (5413) 5413
therapy (5398) 5398
activation (5360) 5360
medicine (5356) 5356
inflammation (5301) 5301
vascular endothelial growth factor a - metabolism (5236) 5236
medicine, research & experimental (5214) 5214
hypoxia (5207) 5207
inhibition (5097) 5097
endothelial cells (5079) 5079
research article (4994) 4994
cancer therapies (4830) 4830
cell proliferation - drug effects (4808) 4808
rodents (4799) 4799
endothelium (4776) 4776
breast cancer (4743) 4743
multidisciplinary sciences (4673) 4673
tumor angiogenesis (4672) 4672
studies (4650) 4650
in-vitro (4596) 4596
immunohistochemistry (4581) 4581
physiological aspects (4569) 4569
neovascularization, pathologic - drug therapy (4445) 4445
in-vivo (4376) 4376
aged, 80 and over (4266) 4266
development and progression (4234) 4234
proliferation (4187) 4187
phosphorylation (4083) 4083
cell growth (4057) 4057
medicine & public health (4033) 4033
growth factors (3977) 3977
disease models, animal (3955) 3955
stem cells (3955) 3955
biology (3935) 3935
prognosis (3931) 3931
mice, nude (3904) 3904
antineoplastic agents - therapeutic use (3882) 3882
genetic aspects (3821) 3821
medical research (3817) 3817
mice, inbred c57bl (3779) 3779
science (3728) 3728
surgery (3643) 3643
tumor-growth (3591) 3591
antineoplastic agents - pharmacology (3586) 3586
survival (3489) 3489
hematology (3488) 3488
intravitreal injections (3409) 3409
macular degeneration (3372) 3372
carcinoma (3367) 3367
growth-factor (3345) 3345
cytokines (3295) 3295
cell adhesion & migration (3284) 3284
signal transduction - drug effects (3227) 3227
apoptosis - drug effects (3215) 3215
neoplasms - drug therapy (3213) 3213
antibodies, monoclonal, humanized (3206) 3206
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (34) 34
Gerstein Science - Stacks (24) 24
Collection Dvlpm't (Acquisitions) - Vendor file (7) 7
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Gerstein Science - Circulation Desk (1) 1
Gerstein Science - Missing (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (86470) 86470
French (560) 560
Japanese (510) 510
German (466) 466
Chinese (358) 358
Spanish (170) 170
Russian (105) 105
Polish (94) 94
Portuguese (74) 74
Korean (41) 41
Hungarian (38) 38
Czech (35) 35
Italian (24) 24
Romanian (22) 22
Dutch (18) 18
Turkish (15) 15
Danish (12) 12
Swedish (11) 11
Finnish (10) 10
Hebrew (9) 9
Norwegian (6) 6
Persian (6) 6
Slovak (4) 4
Croatian (3) 3
Serbian (3) 3
Ukrainian (3) 3
Icelandic (2) 2
Slovenian (2) 2
Arabic (1) 1
Bosnian (1) 1
Hindi (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2006, ISBN 9780470012949, xvii, 350 p., [8] p. of plates
Book
CA: a cancer journal for clinicians, ISSN 0007-9235, 2010, Volume 60, Issue 4, pp. 222 - 243
... Because angiogenesis is a key process in tumor growth, and a limited process in healthy adults, developing angiogenesis inhibitors is a desirable anticancer target for which few... 
TYROSINE KINASE INHIBITORS | CELL LUNG-CANCER | PHASE-III TRIAL | FARNESYL-PROTEIN TRANSFERASE | FACTOR 1-ALPHA | ONCOLOGY | ENDOTHELIAL-GROWTH-FACTOR | HYPOXIA-INDUCIBLE FACTOR-1-ALPHA | FACTOR EXPRESSION | VASCULAR-PERMEABILITY FACTOR | TUMOR-GROWTH | Neoplasms - metabolism | Nucleic Acid Synthesis Inhibitors - pharmacology | Humans | Receptor Protein-Tyrosine Kinases - physiology | Antibodies, Monoclonal - therapeutic use | Receptors, Notch - antagonists & inhibitors | Protein Binding - drug effects | Angiogenesis Inhibitors - therapeutic use | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Neovascularization, Pathologic - prevention & control | Farnesyltranstransferase - antagonists & inhibitors | Thioredoxins - antagonists & inhibitors | Nucleic Acid Synthesis Inhibitors - therapeutic use | Basic Helix-Loop-Helix Transcription Factors - physiology | Antibodies, Monoclonal - pharmacology | Intracellular Signaling Peptides and Proteins - antagonists & inhibitors | Angiogenesis Inhibitors - pharmacology | Receptors, Notch - physiology | Neoplasms - blood supply | Basic Helix-Loop-Helix Transcription Factors - antagonists & inhibitors | Neoplasms - drug therapy | Signal Transduction - drug effects | Cell Transformation, Neoplastic | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Intracellular Signaling Peptides and Proteins - physiology | Complications and side effects | Care and treatment | Ligands (Biochemistry) | Physiological aspects | Development and progression | Dosage and administration | Angiogenesis inhibitors | Neovascularization | Identification and classification | Growth factors | Cancer | Angiogenesis | Pharmacology | FDA approval | Drug therapy | Kinases | Tumors | hypoxia inducible factor (HIF) | kinase inhibitors | growth factors | angiogenesis inhibitors | VEGF | anti-angiogenesis
Journal Article
International journal of molecular sciences, ISSN 1422-0067, 2017, Volume 18, Issue 7, p. 1414
...) and histone acetyltransferases (HAT). HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response... 
Histone deacetylase inhibitors | Anti-angiogenic effect | Cell cycle arrest | Drug combinations | Histone deacetylases | Autophagy | Apoptosis | Cancer | HDAC INHIBITORS | autophagy | SUBEROYLANILIDE HYDROXAMIC ACID | HUMAN LEUKEMIA-CELLS | NITRIC-OXIDE SYNTHASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | TUMOR-SUPPRESSOR GENES | apoptosis | VALPROIC ACID | cell cycle arrest | anti-angiogenic effect | CHEMISTRY, MULTIDISCIPLINARY | drug combinations | CELL LUNG-CANCER | EPITHELIAL-MESENCHYMAL TRANSITION | PHASE-II TRIAL | LONG NONCODING RNA | histone deacetylases | cancer | histone deacetylase inhibitors | Immunomodulation - drug effects | Apoptosis - drug effects | Humans | Angiogenesis Inhibitors - pharmacology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Autophagy - drug effects | Acetylation - drug effects | Animals | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cell Cycle Checkpoints - drug effects | Angiogenesis Inhibitors - therapeutic use | Histone Deacetylase Inhibitors - pharmacology | Antineoplastic Agents - pharmacology | Epigenesis, Genetic - drug effects | Histone Deacetylase Inhibitors - therapeutic use | Gene Expression Regulation, Neoplastic - drug effects | Drug Evaluation, Preclinical
Journal Article
Cellular and molecular life sciences : CMLS, ISSN 1420-9071, 2008, Volume 66, Issue 7, pp. 1163 - 1177
Journal Article
Expert Review of Anticancer Therapy, ISSN 1473-7140, 02/2004, Volume 4, Issue 1, pp. 105 - 128
Brain tumors are a diverse group of malignancies that remain refractory to conventional treatment approaches. Molecular neuro-oncology has now begun to clarify... 
PI3K | signal transduction | angiogenesis | neuro-oncology | mTOR | PTEN | brain tumor | molecular | Akt | SHH/PTCH | Brain tumor | Angiogenesis | Signal transduction | Neuro-oncology | Molecular | Protein Kinases - metabolism | Molecular Biology | Tumor Suppressor Proteins - antagonists & inhibitors | Humans | Receptors, Cell Surface | Brain Neoplasms - blood supply | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Drug Delivery Systems | Hedgehog Proteins | PTEN Phosphohydrolase | Drug Design | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Angiogenesis Inhibitors - therapeutic use | Membrane Proteins - metabolism | Patched Receptors | Protein-Serine-Threonine Kinases - metabolism | Phosphoric Monoester Hydrolases - antagonists & inhibitors | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Tumor Suppressor Proteins - metabolism | Signal Transduction | Enzyme Inhibitors - pharmacology | Angiogenesis Inhibitors - pharmacology | Brain Neoplasms - drug therapy | Enzyme Inhibitors - therapeutic use | Proto-Oncogene Proteins c-akt | Medical Oncology | Protein Kinase Inhibitors | Membrane Proteins - antagonists & inhibitors | Neovascularization, Pathologic - drug therapy | Trans-Activators - metabolism | TOR Serine-Threonine Kinases | Trans-Activators - antagonists & inhibitors | Phosphoric Monoester Hydrolases - metabolism | Patched-1 Receptor | Care and treatment | Brain tumors | Patient outcomes | Development and progression | Genetic aspects | Cellular signal transduction | Research | Gene therapy | Health aspects
Journal Article
International Journal of Molecular Sciences, ISSN 1661-6596, 10/2017, Volume 18, Issue 10, p. 2021
...). Bevacizumab was the first angiogenesis inhibitor approved for the treatment of patients with advanced NSCLC in combination with chemotherapy... 
Nintedanib | Angiogenesis | Ramucirumab | VEGF trap | Vascular endothelial growth factor (VEGF) | Bevacizumab | ramucirumab | PLACEBO-CONTROLLED-TRIAL | MAINTENANCE BEVACIZUMAB | angiogenesis | BIOCHEMISTRY & MOLECULAR BIOLOGY | vascular endothelial growth factor (VEGF) | OPEN-LABEL | COMBINATION | CHEMISTRY, MULTIDISCIPLINARY | CELL LUNG-CANCER | PHASE-III TRIAL | bevacizumab | DOUBLE-BLIND | nintedanib | 1ST-LINE THERAPY | PLUS ERLOTINIB | ENDOTHELIAL GROWTH-FACTOR | Neovascularization, Pathologic - mortality | Niacinamide - analogs & derivatives | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Bevacizumab - therapeutic use | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Neovascularization, Pathologic - pathology | Taxoids - therapeutic use | Clinical Trials, Phase III as Topic | Adenocarcinoma - metabolism | Angiogenesis Inhibitors - therapeutic use | Pyrroles - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Non-Small-Cell Lung - metabolism | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neovascularization, Pathologic - drug therapy | Piperidines - therapeutic use | Quinazolines - therapeutic use | Indoles - therapeutic use | Neovascularization, Pathologic - metabolism | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Adenocarcinoma | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Histology | Metastasis | Patients | Survival | Two phase | Biological activity | Metastases | Chemotherapy | Antiangiogenics | Antiangiogenic agents | Biomarkers | Angiogenesis inhibitors | Tumors
Journal Article